Armstrong, A. W., M. Lebwohl, J. Bagel, T. Schlesinger, S. Banerjee, R. M. Kisa, T. Scharnitz, K. Hoyt, and B. Strober. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s120, doi:10.25251/skin.7.supp.120.